Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEO 90105 in Japanese Subjects With Psoriasis Vulgaris
NCT01422434Phase 3Completed
- Sponsor
- LEO Pharma
- Start
- Jul 2011
- Primary completion
- Apr 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised trial of calcipotriol and betamethasone dipropionate in Psoriasis vulgaris (PV) (3 arms), sponsored by LEO Pharma. Primary endpoint: Change From Baseline in Modified Psoriasis Area and Severity Index at 4 weeks. Started Jul 2011; status: completed.
02
Drugs
calcipotriolbetamethasone dipropionate
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT01422434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01422434.